Programmed Gut–Liver‐Targeted Oral Delivery of Peptide‐Probiotic Nano‐Microsystem for Metabolic Complications of Hyperglycemia and Hyperuricemia
Advanced Healthcare Materials · 04.11.2026
DOI: 10.1002/adhm.71954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 04.11.2026. Verfasst von Junyu Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shenzhen Medical Research Fund.
Abstract (Originalsprache)
Hyperglycemia and hyperuricemia are highly prevalent metabolic comorbidities characterized by systemic metabolic disturbances and complex multi‐organ pathogenesis, urgently requiring synergistic multi‐organ‐targeted therapeutic strategies. Here, we present a programmed gut‐liver‐targeted oral peptide‐probiotic nano‐microsystem for metabolic complications of hyperglycemia and hyperuricemia treatment. The xanthine oxidase (XOD)‐inhibitory peptide PPKNW (P1) was loaded in a layer‐by‐layer reactive oxygen species (ROS)‐responsive nanoparticle (P1NPs), followed by engineering on the surface of probiotic Akkermansia muciniphila ( Akk ), resulting in a peptide‐probiotic nano‐microsystem (P1NPs@ Akk ). After oral administration, P1NPs@ Akk remained stable during gastric passage. Upon reaching intestinal environment, CS and HA layers were progressively removed, exposing the P1‐loaded polymersomes, which were transported across the intestinal epithelium via PAT‐1‐mediated transcytosis. In the liver, P1 was released in response to ROS‐mediated disulfide bond cleavage to inhibit XOD and reduce uric acid synthesis. Meanwhile, Akk was delivered to and colonized in the intestine to regulate glucose metabolism. In a mouse model of combined hyperglycemia and hyperuricemia, P1NPs@ Akk promoted hepatic accumulation of P1 and intestinal enrichment of Akk , resulting in significant reductions in blood glucose and uric acid levels. This work presents a programmed gut–liver‐targeted oral platform that integrates peptide therapy and probiotic intervention for multi‐organ regulation of metabolic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
- Key Laboratory of Bioactive Proteins and Peptides Green Biomanufacturing of Guangdong Higher Education Institutes, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
- Key Laboratory of Industrial Biocatalysis, Ministry of Education, Tsinghua University, Beijing, China.
- Beijing Key Laboratory of Recombinant Protein Synthetic Biomanufacturing, Tsinghua University, Beijing, China.
- Center for Synthetic and Systems Biology, Tsinghua University, Beijing, China.
- Department of Chemical Engineering, Tsinghua University, Beijing, China.
ORCID-Profile: Xupu Xing, Yun Chen, Chang Wen, Haihong Chen, Chong Zhang, Can Yang Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shenzhen Medical Research Fund
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Liu, J., Li, X., Xing, X., Chen, Y., Li, Y., Wen, C., Chen, H., He, Y., Zheng, Y., Xie, J., Chen, X. D., Wang, Y., Zhang, C., Xing, X. H., & Zhang, C. Y. (2026). Programmed Gut–Liver‐Targeted Oral Delivery of Peptide‐Probiotic Nano‐Microsystem for Metabolic Complications of Hyperglycemia and Hyperuricemia. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71954
Vancouver
Liu J, Li X, Xing X, Chen Y, Li Y, Wen C, et al. Programmed Gut–Liver‐Targeted Oral Delivery of Peptide‐Probiotic Nano‐Microsystem for Metabolic Complications of Hyperglycemia and Hyperuricemia. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71954
BibTeX
@article{Liu2026,
author = {Liu, Junyu and Li, Xiaobin and Xing, Xupu and Chen, Yun and Li, Yiting and Wen, Chang and Chen, Haihong and He, Yumao and Zheng, Yilin and Xie, Jin and Chen, Xiao Dong and Wang, Yi and Zhang, Chong and Xing, Xin-Hui and Zhang, Can Yang},
title = {Programmed Gut–Liver‐Targeted Oral Delivery of Peptide‐Probiotic Nano‐Microsystem for Metabolic Complications of Hyperglycemia and Hyperuricemia},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71954}
}
EUVIMED